Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 21, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares, specifically detailing transactions related to employee benefit trusts and share option plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to corporate governance disclosures regarding share ownership and does not contain financial performance data.
Material Changes
The filing reports the following specific transactions regarding directors' interests:
- SmithKline Beecham Employee Benefit Trust: On March 18, 2005, the Trust purchased 256,018 Ordinary shares at a price of £12.25 per share for participants in the Annual Investment Plan. Director John Coombe holds an interest in these shares as a beneficiary of the discretionary fund.
- GlaxoSmithKline Employee Trust (GSK Trust): On March 18, 2005, the GSK Trust transferred 2,991 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe hold an interest in these shares as beneficiaries of the discretionary trust.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document focuses exclusively on the mechanics of share transfers within employee trusts.
Key Facts for Investor Verification
- Verify the total number of shares held by directors John Coombe, Dr. J-P Garnier, and Dr. T Yamada through the respective employee trusts.
- Confirm the pricing of the share purchase (£12.25) against the market price on March 18, 2005.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting conditions for the 2,991 transferred shares.
- Note that this filing does not contain financial results; investors should refer to the company's Form 20-F or interim reports for financial performance.